| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/28/2008 | WO2008102264A2 Stable digestive enzyme compositions |
| 08/28/2008 | WO2008102248A2 An improved monolithic drug delivery system |
| 08/28/2008 | WO2008102247A2 A polyamide rate-modulated monolithic drug delivery system |
| 08/28/2008 | WO2008102235A1 Controlled release formulations of alfuzosin |
| 08/28/2008 | WO2008102192A2 Controlled release pharmaceutical compositions |
| 08/28/2008 | WO2008102150A2 Composition for combating epistaxis |
| 08/28/2008 | WO2008102144A2 Aqueous formulations |
| 08/28/2008 | WO2008102129A1 Delta 9 - tetrahydrocannabinol processing |
| 08/28/2008 | WO2008101943A1 Pharmaceutical metformin hydrochloride formulation and tablet comprising said formulation |
| 08/28/2008 | WO2008101743A2 Pellets comprising an active substance matrix resistant to gastric juice |
| 08/28/2008 | WO2008101723A2 Pharmaceutical composition containing a cholesterol absorption inhibitor |
| 08/28/2008 | WO2008101554A1 Pellets comprising an active substance matrix and a polymer coating, and a method for producing said pellets |
| 08/28/2008 | WO2008101469A2 Pharmaceutical preparation for treating metastases |
| 08/28/2008 | WO2008101375A1 A gastric retentive sustained-release pharmaceutical composition comprising irbesartan |
| 08/28/2008 | WO2008101354A1 Gpr65 as a therapeutic target in allergic airway inflammation |
| 08/28/2008 | WO2008101344A1 Soluble bioactive lipophilic compounds compositions |
| 08/28/2008 | WO2008072985A3 Pour on formulation |
| 08/28/2008 | WO2008064734A3 Medicament with controlled release containing galanthamine |
| 08/28/2008 | WO2008060515A3 Topical compositions comprising polyhydroxy acids and/or lactones for improved cutaneous effects of oxidative therapeutic drugs |
| 08/28/2008 | WO2008060466A3 Individualized dosage determination for local administration of therapeutic particles |
| 08/28/2008 | WO2008058288A3 Sustained release methotrexate formulations and methods of use thereof |
| 08/28/2008 | WO2008057409A3 Sanitizing surfaces |
| 08/28/2008 | WO2008045107A3 Botulinum nanoemulsions |
| 08/28/2008 | WO2008040512A3 Disposal system |
| 08/28/2008 | WO2008014200A3 Cyclosporin compositions |
| 08/28/2008 | WO2008006021A3 Shifter with actuator incorporating shape memory alloy |
| 08/28/2008 | WO2007142867A3 Disposable infusion device with linear peristaltic pump |
| 08/28/2008 | WO2007133808A3 Nano-particles for cosmetic applications |
| 08/28/2008 | WO2007120864A3 Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| 08/28/2008 | WO2007095374A3 Antimicrobial smoke flavor for oral microflora control |
| 08/28/2008 | WO2007089607A3 Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same |
| 08/28/2008 | WO2007005847A3 An electro-osmotic fluid delivery device and method |
| 08/28/2008 | US20080208174 Device for the Controlled Release of a Predefined Quantity of a Substance |
| 08/28/2008 | US20080208165 Methods, systems, and kits for implanting articles |
| 08/28/2008 | US20080207779 Electrically conductive hydrogels |
| 08/28/2008 | US20080207777 Emulsifier System, Emulsion and the Use Thereof |
| 08/28/2008 | US20080207776 Lipid aggregate for delivery of macromolecules into cells |
| 08/28/2008 | US20080207761 Pharmaceutical formulations of modafinil |
| 08/28/2008 | US20080207750 Use of N-Chlorotaurine for Treatment of Oozing Tissue Deficiencies |
| 08/28/2008 | US20080207746 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis; using halogenated xanthene compound |
| 08/28/2008 | US20080207725 Skin disorders; antiinflamamtory agenst; antiallergens |
| 08/28/2008 | US20080207664 Uniform concentration in blood ; oral administering |
| 08/28/2008 | US20080207663 Once daily dosage forms of trospium |
| 08/28/2008 | US20080207662 Uniform blood concentration; sustained release; therapy for bladder disorders |
| 08/28/2008 | US20080207661 Uniform blood concentration; oral administering |
| 08/28/2008 | US20080207624 Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia |
| 08/28/2008 | US20080207600 Pharmaceutical Combination for the Treatment of Cns Functional Disorders |
| 08/28/2008 | US20080207557 A time-release formulation of a water-soluble derivative having the fatty acid moiety removed and an antiinflammatory agent; opoid resistant neuropathic pain, amputation pain or neuralgia; |
| 08/28/2008 | US20080207552 Decoy compositions for treating and preventing brain diseases and disorders |
| 08/28/2008 | US20080207545 Using antisense oligonucleotides, small interfering RNA, and ribozymes to inhibit expression of the human steroid 5 alpha-reductase gene and thereby inhibit formation of dihydrotestosterone: skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia |
| 08/28/2008 | US20080207537 Reducing agent and oxidizing agent are separately disposed and sequentially administered to a nail; oxidizer increases permeability; thioglycolic acid derivative and hydrogen peroxide; psoriasis; fungicides |
| 08/28/2008 | US20080207516 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 08/28/2008 | US20080206378 Anthelmintic Composition |
| 08/28/2008 | US20080206350 Drugs embedded in anionic acrylic acid-methacryilc acid copolymers; extrusion |
| 08/28/2008 | US20080206349 Emulsion of aqueous solvent, soluble/dispersable carrier, and volatile immiscible liquid phase |
| 08/28/2008 | US20080206348 Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers |
| 08/28/2008 | US20080206347 With fatty acid pre-absorbed on surface; for oral administration without causing side effects to the upper gastrointestinal region |
| 08/28/2008 | US20080206346 Preparation of powder agglomerates |
| 08/28/2008 | US20080206345 Abamectin, lambda-cyhalothrin and lufenuron; nematocides |
| 08/28/2008 | US20080206344 Endocytotic particles |
| 08/28/2008 | US20080206343 Contacting with sodium butyrate; for treatment of trauma, inflammation, and degenerative disorders of the liver; model mouse |
| 08/28/2008 | US20080206342 Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin |
| 08/28/2008 | US20080206341 Lipid Nanoparticles as Vehicles for Nucleic Acids, Process for Their Preparation and Use |
| 08/28/2008 | US20080206340 Galactomannans and/or Glucomannans For Increasing the Bioavailability of Active Substances |
| 08/28/2008 | US20080206339 Very-pure superporous hydrogels having outstanding swelling properties |
| 08/28/2008 | US20080206338 Controlled release formulations of an alpha-adrenergic receptor antagonist |
| 08/28/2008 | US20080206337 Shell semipermeable to liquid medium comprised of a water insoluble film forming polymer and a gelling agent; second shell different than the firstin contact with core exterior surface; drug delivery of one or more active ingredients in a controlled or delayed release |
| 08/28/2008 | US20080206336 Once-a-day modified release tablet formulation rosiglitazone and metformin; enteric coating to control the rate of release; erosion of coating under pre-determined pH conditions; diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose |
| 08/28/2008 | US20080206335 Inert non-pareil core, fluvoxamine layer over core, rate-controlling membrane coating; fluvoxamine released over a period of 12 hours or more; once-daily oral administration |
| 08/28/2008 | US20080206334 Hydrophilic polysaccharide polymer mixture of chitosan, xanthan gum, sodium bicarbonate buffering agent; active agent is dispersed or embedded within the inactive matrix; tablets generated by direct compaction |
| 08/28/2008 | US20080206333 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 08/28/2008 | US20080206332 Tablet of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid or a pharmaceutically acceptable salt; polyvinyl acetate phthalate release rate modifying polymer; hydroxypropylmethyl cellulose polymer; neuropathies |
| 08/28/2008 | US20080206331 Tablet comprising efletirizine and pseudoephedrine |
| 08/28/2008 | US20080206330 Pharmaceutical Composition |
| 08/28/2008 | US20080206329 Tablet; water-insoluble release-retarding ethyl cellulose, ammonioalkyl methacrylate copolymer; simple, conventional pharmaceutical processing; no complex retention mechanisms; stable, bioequivalent to commercially available CIPRO XR; maintains therapeutic blood levels; enables once-a-day administration |
| 08/28/2008 | US20080206328 Hypocholesterolemic Compositions Comprising a Statin and an Antiflatulent Agent |
| 08/28/2008 | US20080206327 Phentermine weight-loss drug; excipients, bulking agents, binders, disintegrating agents, acidifying agents, sweetening agents, lubricants, flavorings; child, adolesent obesity |
| 08/28/2008 | US20080206326 Liquid salt of a non-steroidal anti-inflammatory drug, flurbiprofen; propylene glycol solvent; sucrose, glucose, sorbitol, xylitol, maltitol, a hydrogenated starch hydrosylate, molten lozenge-forming composition; sore throats |
| 08/28/2008 | US20080206325 Encapsulated Active Ingredients, Methods of Preparation and Their Use |
| 08/28/2008 | US20080206324 pharmaceutically active substance embedded in a polymer matrix of cationic (meth)acrylate copolymer having quaternary ammonium groups (EUDRAGITS"); Polymer coating is anionic (meth)acrylate copolymer |
| 08/28/2008 | US20080206323 Soft Gelatin Capsules |
| 08/28/2008 | US20080206322 Advantageous properties when administered orally; consistency of pharmacokinetic behavior achieved; exhibits less fatty food interaction; time release coating reduces variation in mycophenolic acid exposure from one day to the next or from day time to night |
| 08/28/2008 | US20080206321 Sucrose acetate isobutyrate; cellulose acetate butyrate; solvent; rheology modifier; opioid drug; dosage form and formulation; desirable release kinetics; not susceptible to crushing or powdering; not susceptible to extraction using ethanol or water; abuse deterrence and reduced risk of diversion |
| 08/28/2008 | US20080206320 Alopecia therapy using tetrazole compound |
| 08/28/2008 | US20080206319 Mucosal adjuvants elicit strong balanced or adjusted immune response of humoral, cellular components; prophylaxis or treatment of infectious diseases or cancer; non-toxic; employed with a wide variety of active ingredients to be assisted in conventional or novel vaccines |
| 08/28/2008 | US20080206318 Administering complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the tumor-associated antigen is CA 125 for therapy of oncological disease |
| 08/28/2008 | US20080206317 Ternary Non-Lamellar Lipid Compositions |
| 08/28/2008 | US20080206316 Nutraceutical; chromium atoms bonded to fatty acids; linoleic acid, linolenic acid, gamma-linolenic acid, arachidonic acid; and transition metal, an alkaline metal, alkaline earth metal, rare earth metal, or metalloid; nutritional supplements, food stuffs, and pharmaceutical compositions |
| 08/28/2008 | US20080206315 Drug containing adhesive preparation |
| 08/28/2008 | US20080206314 patches has pressure-sensitive adhesive matrix containing a polyisobutylene, free of permeation enhancer, for drug deliverying sufentanil through the skin to provide an analgesic effect, pain management; sustained release, side effect reduction, consistent concentration in blood |
| 08/28/2008 | US20080206313 Nutraceutical; vitamin B, amine oxidase enzyme inhibitor of semicarbazide-sensitive amine oxidases; additive to a foodstuff or as a dietary supplement; atherosclerosis, vascular retinopathies, retinopathy, glomerulosclerosis, nephropathy, nephrotic syndrome, polyneuropathy, mononeuropathies |
| 08/28/2008 | US20080206312 Therapeutic Morpholino-Substituted Compounds |
| 08/28/2008 | US20080206311 Sucrase Activity Inhibitor, Glucoamylase Activity Inhibitor and Food and Feed Containing the Same |
| 08/28/2008 | US20080206309 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 08/28/2008 | US20080206308 comprising a biodegradable unsaturated polymer selecting from polypropylene fumarate and polycaprolactone fumarate and a curing agent to form a porous scaffold in an mold or in a body cavity; for tissue regeneration; drug delivery devices; biodegradable, biocompatible scaffolds for tissue engineering |
| 08/28/2008 | US20080206304 Medical devices having polymeric regions based on styrene-isobutylene copolymers |
| 08/28/2008 | US20080206303 Prolonged Release Formulations Comprising Anastrozole |
| 08/28/2008 | US20080206298 Enhanced biological autologous tissue adhesive composition and methods of preparation and use |
| 08/28/2008 | US20080206296 Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
| 08/28/2008 | US20080206293 Absorbent substrate with a non-leaching antimicrobial activity and a controlled-release bioactive agent. |